Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis

Summary

Platelet adhesion and aggregation at the sites of vascular injury are key events for thrombosis and haemostasis. It has been well demonstrated that interaction between glycoprotein (GP) Ib and von Willebrand factor (VWF) initiates platelet adhesion and contributes to platelet aggregation, particularly at high shear. GPIb has long been suggested as a desirable antithrombotic target, but anti-GPIb therapy has never been successfully developed. Here, we evaluated the antithrombotic potential of Anfibatide, a novel snake venom-derived GPIb antagonist. We found Anfibatide inhibited washed murine platelet aggregation induced by ristocetin and recombinant murine VWF. It also blocked botrocetin-induced binding of murine plasma VWF to recombinant human GPIb . Interestingly, Anfibatide did not inhibit botrocetin- induced aggregation of platelet-rich plasma, indicating that its binding site may differ from other snake venom-derived GPIb antagonists. Anfibatide strongly inhibited platelet adhesion, aggregation, and thrombus formation in perfusion chambers at high shear conditions and efficiently dissolved preformed thrombi. Anfibatide also inhibited thrombus growth at low shear conditions, though less than at high shear. Using intravital microscopy, we found that Anfibatide markedly inhibited thrombosis in laser-injured cremaster vessels and prevented vessel occlusion in FeCl₃-injured mesenteric vessels. Importantly, Anfibatide further inhibited residual thrombosis in VWF-deficient mice, suggesting that Anfibatide has additional antithrombotic effect beyond its inhibitory role in GPIb-VWF interaction. Anfibatide did not significantly cause platelet activation, prolong tail bleeding time, or cause bleeding diathesis in mice. Thus, consistent with the data from an ongoing clinical trial, the data from this study suggests that Anfibatide is a potent and safe antithrombotic agent.

Keywords

Antithrombotic agent - snake venoms - platelet inhibitor - glycoprotein Ib-IX-V complex

^* X. Lei and A. Reheman contributed equally to this work.

• References

• 1 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-1234.
• 2 Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost 2011; 9 (Suppl. 01) 92-104.
• 3 Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109: 5087-5095.
• 4 Ni H, Denis CV, Subbarao S. et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-392.
• 5 Yang H, Reheman A, Chen P. et al. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost 2006; 4: 2230-2237.
• 6 Reheman A, Yang H, Zhu G. et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood 2009; 113: 1809-1817.
• 7 Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008; 112: 3011-3025.
• 8 Fontayne A, Meiring M, Lamprecht S. et al. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost 2008; 100: 670-677.
• 9 Luo SZ, Mo X, Afshar-Kharghan V. et al. Glycoprotein Ibalpha forms disulfide bonds with 2 glycoprotein Ibbeta subunits in the resting platelet. Blood 2007; 109: 603-609.
• 10 Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008; 117: 1449-1459.
• 11 Miura S, Li CQ, Cao Z. et al. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem 2000; 275: 7539-7546.
• 12 Gilbert JC, DeFeo-Fraulini T, Hutabarat RM. et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116: 2678-2686.
• 13 Bergmeier W, Piffath CL, Goerge T. et al. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci USA 2006; 103: 16900-16905.
• 14 Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost 2008; 99: 264-270.
• 15 Vanhoorelbeke K, Ulrichts H, Van de Walle G. et al. Inhibition of platelet glyco-protein Ib and its antithrombotic potential. Curr Pharm Des 2007; 13: 2684-2697.
• 16 Wang WJ, Huang TF. A novel tetrameric venom protein, agglucetin from Agkis-trodon acutus, acts as a glycoprotein Ib agonist. Thromb Haemost 2001; 86: 1077-1086.
• 17 Gao Y, Ge H, Chen H. et al. Crystal structure of agkisacucetin, a Gpib-binding snake C-type lectin that inhibits platelet adhesion and aggregation. Proteins 2012; 80: 1707-1711.
• 18 Li WF, Chen L, Li XM. et al. A C-type lectin-like protein from Agkistrodon acu-tus venom binds to both platelet glycoprotein Ib and coagulation factor IX/fac- tor X. Biochem Biophys Res Commun 2005; 332: 904-912.
• 19 Denis C, Methia N, Frenette PS. et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998; 95: 9524-9529.
• 20 De Meyer SF, Vandeputte N, Pareyn I. et al. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol 2008; 28: 1621-1626.
• 21 Vanhoorelbeke K, Cauwenberghs N, Vauterin S. et al. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 107-113.
• 22 Rayes J, Hollestelle MJ, Legendre P. et al. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood 2010; 115: 4870-4877.
• 23 De Meyer SF, Budde U, Deckmyn H. et al. In vivo von Willebrand factor size heterogeneity in spite of the clinical deficiency of ADAMTS-13. J Thromb Hae-most 2011; 9: 2506-2508.
• 24 Reheman A, Gross P, Yang H. et al. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost 2005; 3: 875-883.
• 25 Reheman A, Tasneem S, Ni H. et al. Mice with deleted multimerin 1 and alpha-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1. Thromb Res 2010; 125: e177-183.
• 26 Xu X, Wu J, Zhai Z. et al. A novel fibrinogen Bbeta chain frameshift mutation in a patient with severe congenital hypofibrinogenaemia. Thromb Haemost 2006; 95: 931-935.
• 27 Wong C, Liu Y, Yip J. et al. CEACAM1 negatively regulates platelet-collagen interactions and thrombus growth in vitro and in vivo. Blood 2009; 113: 1818-1828.
• 28 Matsui H, Sugimoto M, Mizuno T. et al. Distinct and concerted functions of von Willebrand factor and fibrinogen in mural thrombus growth under high shear flow. Blood 2002; 100: 3604-3610.
• 29 Ni H, Papalia JM, Degen JL. et al. Control of thrombus embolization and fibro-nectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood 2003; 102: 3609-3614.
• 30 Yang Y, Shi Z, Reheman A. et al. Plant food delphinidin-3-glucoside significantly inhibits platelet activation and thrombosis: novel protective roles against cardiovascular diseases. PloS one 2012; 7: e37323
• 31 Gui T, Reheman A, Ni H. et al. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost 2009; 7: 1843-1851.
• 32 Falati S, Gross P, Merrill-Skoloff G. et al. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002; 8: 1175-1181.
• 33 Chen J, Reheman A, Gushiken FC. et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011; 121: 593-603.
• 34 Clemetson KJ. Snaclecs (snake C-type lectins) that inhibit or activate platelets by binding to receptors. Toxicon 2010; 56: 1236-1246.
• 35 Zha XD, Liu J, Xu KS. cDNA cloning, sequence analysis, and recombinant expression of akitonin beta, a C-type lectin-like protein from Agkistrodon acutus. Acta Pharmacol Sin 2004; 25: 372-377.
• 36 Fujimura Y, Ikeda Y, Miura S. et al. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib. Thromb Haemost 1995; 74: 743-750.
• 37 Howard MA, Firkin BG. Ristocetin--a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-369.
• 38 Brinkhous KM, Read MS, Fricke WA. et al. Botrocetin (venom coagglutinin): reaction with a broad spectrum of multimeric forms of factor VIII macromol-ecular complex. Proc Natl Acad Sci USA 1983; 80: 1463-1466.
• 39 Andrews RK, Gardiner EE, Shen Y. et al. Glycoprotein Ib-IX-V. Int J Biochem Cell Biol 2003; 35: 1170-1174.
• 40 Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-666.
• 41 Mendolicchio GL, Ruggeri ZM. New perspectives on von Willebrand factor functions in hemostasis and thrombosis. Semin Hematol 2005; 42: 5-14.
• 42 Brill A, Fuchs TA, Chauhan AK. et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011; 117: 1400-1407.
• 43 Andre P, Denis CV, Ware J. et al. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 2000; 96: 3322-3328.
• 44 Jurk K, Clemetson KJ, de Groot PG. et al. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. Faseb J 2003; 17: 1490-1492.
• 45 Anderson PR, Gogo PB, Ahmed B. et al. Two hour bivalirudin infusion after PCI for ST elevation myocardial infarction. J Thromb Thrombolysis 2011; 31: 401-406.
• 46 Ndrepepa G, Berger PB, Mehilli J. et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51: 690-697.
• 47 Elcioglu OC, Ozkok A, Akpinar TS. et al. Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review. Int J Hematol 2012; 96: 370-375.
• 48 Chalouhi N, Jabbour P, Kung D. et al. Safety and efficacy of tirofiban in stent-as-sisted coil embolization of intracranial aneurysms. Neurosurgery 2012; 71: 710-714.
• 49 Hermanides RS, Ottervanger JP, ten Berg JM. et al. Net clinical benefit of pre-hospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myo-cardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. J Invasive Cardiol 2012; 24: 84-89.
• 50 Guo J, Xu M, Xi Y. Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty. Tex Heart Inst J 2012; 39: 99-103.